Crinetics Pharmaceuticals, Inc.
CRNX
Pozycja w akcjach
#2197
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Cena akcji
$84.95
Ostatnia synchronizacja: 2026-09-01
Kapitalizacja rynkowa
$9.00B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
110.12%
Kraj
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Kategoria
Healthcare
Historia ceny akcji dla Crinetics Pharmaceuticals, Inc. (CRNX)
Najwyższa cena zamknięcia: $84.95 dnia 2026-09-01
Najniższa cena zamknięcia: $24.52 dnia 2018-07-01
Najniższa cena zamknięcia: $24.52 dnia 2018-07-01
Historia cen akcji firmy Crinetics Pharmaceuticals, Inc. od 2018 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 3.89% |
| 2025 | -13.25% |
| 2024 | 59.38% |
| 2023 | 103.03% |
| 2022 | -34.46% |
| 2021 | 91.75% |
| 2020 | -37.94% |
| 2019 | -30.68% |
| 2018 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $536.91 | 25.90% |
US
|
|
| $230.20 | 757.36% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $892.44 | 9.61% |
NL
|
|
| $291.76 | 2.51% |
BE
|
